Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the antibody drug conjugates market?

In recent times, there’s been a massive expansion in the size of the antibody drug conjugates market. This market, which was valued at $13.57 billion in 2024, is projected to shoot up to $16.66 billion in 2025, showcasing a compound annual growth rate (CAGR) of 22.7%. The historic growth in the market can be linked back to multiple factors, including an increased prevalence of cancer, successful clinical trials and approved drugs, strategic partnerships, heightened investment in research and development, as well as strategies aimed at expanding the market.

What will be the antibody drug conjugates market size in the future?

The size of the rolled and drawn steel market is anticipated to witness robust growth in the upcoming years, with projections estimating it will reach $365.53 billion in 2029, indicating a compound annual growth rate (CAGR) of 5.6%. The surge within this forecast period can be linked to factors such as the development of renewable energy infrastructure, the dispersion of electric vehicles (EV), emphasis on sustainable construction, the evolution of smart cities and the integration of IoT, along with stringent environmental regulations. Major trends in the forecast period comprise of infrastructure investments, innovative breakthroughs in steel processing technology, advanced progress in steel production, integration of industry 4.0, and the digitalization of supply chains.

Get your antibody drug conjugates market report here!

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

What main drivers are fueling expansion in the antibody drug conjugates market?

The growth of the antibody-drug conjugates market is being fueled by an escalating global prevalence of cancer. The primary triggers for most types of cancer are factors such as obesity, smoking, alcohol consumption, and unhealthy eating patterns. A forecast by Cancer Research UK suggests that by 2040, the annual rate of new cancer cases will reach 27.5 million. This surging incidence of cancer is anticipated to elevate the need for antibody-drug conjugates, thus promoting the expansion of the market.

What key areas define the segmentation of the global antibody drug conjugates market?

The antibody drug conjugates market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types

2) By Product: Adcertis, Kadcyla, Other Products

3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology

4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications

5) By End User: Hospital, Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies, IgM-based Monoclonal Antibodies, Bispecific Antibodies

2) By Linker: Cleavable Linkers, Non-cleavable Linkers, Stable Linkers

3) By Drug/Toxin: Cytotoxic Drugs, Chemotherapeutic Agents, Radioisotopes

4) By Other Types: Enzyme-Targeted ADCs, Antibody-Drug Conjugates with Immune Modulators

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp

Who are the dominant players expanding their reach in the antibody drug conjugates market?

Major companies operating in the antibody drug conjugates market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA

How are evolving market trends shaping antibody drug conjugates Strategies?

The production of antibody-drug conjugates is supervised by several regulatory authorities, including the U.S. Food and Drug Administration. In the United States, there are no specific regulatory guidance for ADC development, so the FDA adheres to existing small drug and monoclonal antibodies regulations. The product quality departments within the FDA, such as the Office of Biotechnology Products and Office of Pharmaceutical Quality, mainly oversee the manufacture of the antibody portion of the ADC and the control plan for the antibody intermediate. They are also responsible for the regulation of the drug substance (DS) and drug product (DP). The review of the payload and linker’s adequacy, conjugation reactions, and parts of the control strategy primarily falls under the jurisdiction of the small molecule review groups in the Office of Pharmaceutical Quality.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2569

Which regions are emerging as leaders in the antibody drug conjugates market?

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2024. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: